| Date | Time | Source | Headline | Symbol | Company |
| 08/23/2010 | 2:07PM | Dow Jones News | INTERVIEW: Novo Nordisk To Test Victoza In Anti-Obesity - CEO | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/19/2010 | 9:52AM | Marketwired | Analyst Research on Dendreon and Amylin Pharmaceuticals - Biotech Stocks Looking Averagely Attractive | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/16/2010 | 3:29PM | Dow Jones News | UPDATE: Icahn Increases Exposure To Energy Companies In 2Q | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/16/2010 | 1:32PM | Dow Jones News | Icahn Increases Exposure To Energy Companies In 2Q | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/13/2010 | 12:05PM | Dow Jones News | Lilly's Latest Patent Loss Pressures Its Deal-Making Efforts | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/05/2010 | 4:06PM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/27/2010 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/21/2010 | 4:12PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/21/2010 | 4:05PM | PR Newswire (US) | Amylin Pharmaceuticals Reports Second Quarter Financial Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/14/2010 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Webcast Second Quarter Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2010 | 12:00PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2010 | 12:00PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2010 | 12:00PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2010 | 11:59AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2010 | 10:00AM | PR Newswire (US) | Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatm | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2010 | 10:00AM | PR Newswire (US) | Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Fin | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2010 | 10:00AM | PR Newswire (US) | Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2010 | 10:00AM | PR Newswire (US) | Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2010 | 9:00AM | Business Wire | BYDUREON™ Safety and Tolerability Pooled Summary Data Presented at ADA 2010 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2010 | 8:45AM | PR Newswire (US) | BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/23/2010 | 3:22PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/21/2010 | 9:15AM | GlobeNewswire Inc. | Liberty Analytics Co. Initiates Independent Research Coverage on Amylin Pharmaceuticals, Inc. | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/18/2010 | 8:16AM | Dow Jones News | CORRECT: Roche Diabetes Drug Faces Delay On Safety Action | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/18/2010 | 5:41AM | Dow Jones News | 2nd UPDATE: Roche Diabetes Drug Faces Delay On Safety Action | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/18/2010 | 4:08AM | Dow Jones News | UPDATE: Roche Diabetes Drug Faces Delay Due To Safety Action | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/17/2010 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present New Data and Insights From the Company's Diabetes Programs at ADA 2010 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/15/2010 | 4:06PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/15/2010 | 8:15AM | Business Wire | DURATION-4 Study Results: BYDUREON™ Efficacy and Tolerability Profile Extended to Monotherapy Treatment | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/15/2010 | 8:00AM | PR Newswire (US) | DURATION-4 Study Results Released | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/15/2010 | 8:00AM | PR Newswire (US) | DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |